Tompkins Financial’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-53
| Closed | -$10.1K | – | 645 |
|
|
2025
Q3 | $10.1K | Hold |
53
| – | – | ﹤0.01% | 444 |
|
|
2025
Q2 | $9.52K | Hold |
53
| – | – | ﹤0.01% | 447 |
|
|
2025
Q1 | $8.97K | Hold |
53
| – | – | ﹤0.01% | 451 |
|
|
2024
Q4 | $8K | Hold |
53
| – | – | ﹤0.01% | 443 |
|
|
2024
Q3 | $8.23K | Buy |
+53
| New | +$7.92K | ﹤0.01% | 488 |
|
|
2024
Q2 | – | Sell |
-52
| Closed | -$6.92K | – | 600 |
|
|
2024
Q1 | $6.92K | Hold |
52
| – | – | ﹤0.01% | 528 |
|
|
2023
Q4 | $7.17K | Buy |
+52
| New | +$6.84K | ﹤0.01% | 517 |
|
|
2023
Q1 | – | Sell |
-480
| Closed | -$75K | – | 636 |
|
|
2022
Q4 | $75K | Hold |
480
| – | – | 0.01% | 295 |
|
|
2022
Q3 | $59K | Hold |
480
| – | – | 0.01% | 312 |
|
|
2022
Q2 | $64K | Hold |
480
| – | – | 0.01% | 310 |
|
|
2022
Q1 | $66K | Buy |
+480
| New | +$66.9K | 0.01% | 324 |
|
|
2021
Q1 | $90K | Sell |
700
-107
| -13% | -$13.2K | 0.02% | 195 |
|
|
2020
Q4 | $96K | Buy |
807
+107
| +15% | +$13K | 0.02% | 180 |
|
|
2020
Q3 | $80K | Hold |
700
| – | – | 0.02% | 201 |
|
|
2020
Q2 | $80K | Hold |
700
| – | – | 0.02% | 196 |
|
|
2020
Q1 | $56K | Hold |
700
| – | – | 0.01% | 226 |
|
|
2019
Q4 | $75K | Hold |
700
| – | – | 0.01% | 227 |
|
|
2019
Q3 | $75K | Hold |
700
| – | – | 0.02% | 200 |
|
|
2019
Q2 | $71K | Hold |
700
| – | – | 0.01% | 210 |
|
|
2019
Q1 | $63K | Hold |
700
| – | – | 0.01% | 216 |
|
|
2018
Q4 | $58K | Hold |
700
| – | – | 0.01% | 218 |
|
|
2018
Q3 | $76K | Hold |
700
| – | – | 0.02% | 223 |
|
|
2018
Q2 | $77K | Hold |
700
| – | – | 0.02% | 223 |
|
|
2018
Q1 | $70K | Hold |
700
| – | – | 0.02% | 223 |
|
|
2017
Q4 | $69K | Hold |
700
| – | – | 0.02% | 205 |
|
|
2017
Q3 | $66K | Hold |
700
| – | – | 0.02% | 206 |
|
|
2017
Q2 | $78K | Hold |
700
| – | – | 0.02% | 190 |
|
|
2017
Q1 | $69K | Sell |
700
-22
| -3% | -$2.1K | 0.02% | 196 |
|
|
2016
Q4 | $66K | Hold |
722
| – | – | 0.02% | 192 |
|
|
2016
Q3 | $61K | Hold |
722
| – | – | 0.02% | 200 |
|
|
2016
Q2 | $59K | Hold |
722
| – | – | 0.02% | 234 |
|
|
2016
Q1 | $52K | Hold |
722
| – | – | 0.02% | 239 |
|
|
2015
Q4 | $51K | Sell |
722
-128
| -15% | -$8.61K | 0.02% | 274 |
|
|
2015
Q3 | $53K | Buy |
850
+500
| +143% | +$34.9K | 0.02% | 261 |
|
|
2015
Q2 | $25K | Hold |
350
| – | – | 0.01% | 354 |
|
|
2015
Q1 | $27K | Buy |
+350
| New | +$25.1K | 0.01% | 355 |
|
Other funds holding DGX
Tompkins Financial's DGX Position: Q4 2025 in Review
Tompkins Financial sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 53 shares — an estimated $10.1K sold.
Tompkins Financial first reported a position in DGX in Q1 2015 and held it in 36 quarters. The position peaked at $96K in Q4 2020. 1,050 funds tracked by Wall St. Rank hold DGX as of Q4 2025.
- Tompkins Financial reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
- Tompkins Financial sold 53 Quest Diagnostics shares in Q4 2025, an estimated $10.1K.
- Tompkins Financial first reported a position in Quest Diagnostics in Q1 2015 and held it in 36 quarters.
- Tompkins Financial's Quest Diagnostics position peaked at $96K in Q4 2020.
- 1,050 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.
Based on Tompkins Financial's 13F filing for Q4 2025, filed 8 Jan 2026.